PDVI

Precision Dermatology was a specialized pharmaceutical company focused on the development and commercialization of high-quality products for the dermatology market. Formed through the merger of Onset Therapeutics and Triax Pharmaceuticals, the company built a robust portfolio of prescription brands, including Locoid, Hylatopic, Clindagel, and Benzaclin. Precision Dermatology was acquired by Valeant Pharmaceuticals in 2014 for approximately $475 million in cash, plus potential milestone payments. The acquisition significantly expanded Valeant's dermatology presence by integrating a specialized sales force and a diverse range of topical treatments for conditions such as acne and dermatitis.